Successful treatment of Seborrheic dermatitis with Sebacare100, a non-steroidal product

SebaCare100™ (Sebaclear™), a non steroidal product was proven in a clinically controlled dermatological study to be safe and highly effective in the treatment of Seborrheic dermatitis.
 
 
Sebacare100
Sebacare100
NEW YORK - Oct. 30, 2013 - PRLog -- Seborrheic dermatitis is a common disorder, in both genders.  Suspected ethiology includes inherited predisposition and   proliferation of a fungus called Pityrosporum ovale- leading to local inflammation, thickening of stratum corneum, excessive scale and possible itching.  Steroidal creams and solutions are often prescribed  for  seborrheic  dermatitis leading to  temporary relief.  Nevertheless, long-term use of  steroid  topicals  may  cause  skin atrophy, capillary  enlargement  and  quick  recurrence.

This clinical  study  conducted by  Therapy of Seborrheic dermatitis with Sebacare100, a non-steroidal product: Mycological and Clinical study.

Professor Avner Shemer, Sheba Medical Center Department of Dermatology and Department of Dermatology, Tel Aviv University, Israel. was designed to test a novel  non-steroidal product,  SebaCare100™ (Sebaclear™) developed  in Israel  for the treatment of  facial  and  scalp  Seborrheic  dermatitis. The tested product is a clear liquid containing  proprietary  formulation of non-steroidal ingredients; Australian  tea tree oil , chamomile and salicylic acid .

The product has been tested on 25 volunteers with facial  and  scalp Seborrheic  dermatitis on  at least two of  four  skin areas . Sides of the nose, between the eyebrows, forehead and scalp. We included patients  were aged 16 and over, that  did  not receive any other  treatment  for  their  condition in the last  3  months.  Treatment duration was two months. The patient was instructed to apply a small amount of the product on his finger twice a day on the affected area for the first month and  continue  twice  a week  for  another month.

The volunteers were examined and photographed before treatment, during the second week, fourth week and eighth week of starting treatment. Patients were evaluated in each session and completed a questionnaire to assess efficacy of treatment.

Response to treatment was classified by four levels. 0 = No Response ,  1= slight improvement, 2= moderate improvement and 3 = excellent improvement/complete healing. Medical evaluation of the results showed moderate improvement or more in  93.75 percent of patients at the end of two weeks of  treatment and in 100 % of patients after 4 weeks of treatment.

The  SebaCare100™ (Sebaclear™) was  proven  to  be  safe  and  highly  effective  in the  treatment  of  mild  to moderate  Seborrheic  dermatitis.   As a  non steroidal  product  the  SebaCare100™ (Sebaclear™) may offer  a  significant  value  over  current  steroid  containing  medication  for  both  treatment and long time  prevention.

The  product  is  availble  for sale on:    http://goo.gl/NbXR9q

More details on :

www.skintricks.com

Media Contact
Rational Mind Ltd.
***@rationalmind.co.il
End
Source: » Follow
Email:***@rationalmind.co.il Email Verified
Tags:Seborrhea, Seborrheic Dermatitis, Sebacare100, Sebaclear, Dermatology
Industry:Beauty, Health
Location:New York City - New York - United States
Subject:Surveys
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Rationalmind Ltd. News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share